Vertex Pharmaceuticals ( VRTX) plunged after Q2 earnings and is now down 21% over the past year. The company has historically ...

Reshma Kewalramani, the Mumbai-born CEO of Vertex Pharmaceuticals, secures a spot on Fortune's 2025 list of the 100 Most ...

NEW YORK, NY-Reshma Kewalramani, the Mumbai-born CEO of Vertex Pharmaceuticals, has been named one of the 100 Most Powerful ...

Lilly paid $47.5 million upfront to license the non-opioid pain drug candidate CNTX-0290 from Centrexion in 2019. The SSTR4 ...

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

Vertex's late-stage pipeline also gives investors several lottery tickets with great odds. The drugmaker is evaluating ...

Vertex Pharmaceuticals recently reported a significant revenue jump to $2,965 million in Q2 2025. Despite this success, the ...

Kewalramani, CEO of Vertex Pharmaceuticals, joins Fortune's 100 Most Powerful People in Business. Ranked 62nd, she is the 1st ...

Topline results reveal that VX-993 did not meet its primary endpoints, meaning Vertex will discontinue its development.

On Fortune’s list of the 100 Most Powerful People in Business, a Mumbai-born woman rubs shoulders with the likes of Mark Zuckerberg and Mukesh Ambani ...

I think that's the case with Vertex. Here are seven reasons why Vertex is a no-brainer stock to buy on the dip.

Vertex Pharmaceuticals Inc. fell after an experimental pain drug failed to provide post-surgery benefits and US regulators ...